Finding new ways to improve flu vaccines using the body's immune system
Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza
This study is looking for new ways to make flu vaccines work better by using special ingredients that help your immune system respond stronger, and it's being tested in animals to see if it can lead to better protection for people against the flu.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11141525 on NIH RePORTER |
What this research studies
This research focuses on discovering new adjuvants, which are substances that enhance the effectiveness of vaccines against influenza. By exploring how the innate immune system can be modulated, the researchers aim to improve the body's response to vaccines, leading to better protection against the flu. The approach involves testing these adjuvants in animal models to evaluate their ability to boost immune responses and create long-lasting immunity. If successful, this research could lead to more effective flu vaccines for humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of influenza, including those with weakened immune systems or chronic health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective influenza vaccines that provide better protection and longer-lasting immunity.
How similar studies have performed: Other research has shown promise in enhancing vaccine efficacy through the use of novel adjuvants, indicating that this approach could be successful.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Esser-Kahn, Aaron — University of Chicago
- Study coordinator: Esser-Kahn, Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.